ClinicalTrials.gg
RecruitingNCT06293053Updated Oct 13, 2026

A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis

A Phase 3 interventional study of Dupilumab in Prurigo Nodularis, sponsored by Sanofi. Recruiting at 15 sites in United States. Open to participants aged 6 Months to 17 Years. Per ClinicalTrials.gov, last updated 2026-10-13.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Started May 2024; still recruiting 2 years 6 months later.
Updated Oct 13, 2026Eligibility revised3 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
18
Allocation
Not applicable
Ages
6 Months to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 23 studies in Prurigo with a site in United States — 4 open to participants now, 8 under way, 4 of them phase 3. Prurigo · United States.

Planned enrollment
18th of 21
18 · median 140
Started
2024
with 6 others
Phase 3
10 of 23
1 open now
Registered
15th of 23
by date
Lead sponsor
2 of 23
Sanofi

Among the 23 studies in Prurigo with a site in United States, this one is the 18th largest by planned enrollment of the 21 interventional ones that give a count, is one of 7 that started in 2024, is one of 10 in phase 3, and was the 15th registered.

Prurigo

38 studies on the registry are indexed under Prurigo; 10 are open to participants now.

Browse Prurigo studies →

Open to participants now

4 of the 23 studies in Prurigo with a site in United States are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 7 Prurigo studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 6 Months to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Prurigo with a site in United States, or all of them as a file.
02

Study summary

This is a Phase 3, multicenter, open-label, pharmacokinetics (PK)/safety study.

The study consists of 3 periods:

  • Screening period: 2 to 4 weeks.
  • Treatment period: 24 weeks.
  • Post-intervention follow-up period: 16 weeks. The study duration will be approximately 42 to 44 weeks for each participant (including screening, treatment, and follow-up periods).

The total number of planned study visits for each participant will be 6.

03

Conditions studied

  • Prurigo Nodularis

Browse trials for

04

Who can participate

The criteria were revised on the registry on Oct 13, 2026. See what changed

Ages eligible
6 Months to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must be ≥6 months to \<18 years of age, at the time of signing the .
  • A clinical diagnosis of prurigo nodularis (PN) at least 3 months prior to screening, an Investigator's global assessment for prurigo nodularis stage (IGA PN-S) score of ≥2 with presence of ≥6 pruriginous lesions at Baseline. The lesions should be present on ≥2 different body surface areas at Baseline.
  • On the worst itch numerical rating scale (WI-NRS) (for participants aged ≥6 years to \<18 years old at the screening visit) or worst-scratch/itch NRS (for participants aged ≥6 months to \<6 years at the screening visit) ranging from 0 to 10, participants must have an average worst itch score of ≥7 in the 7 days prior to Day 1.

NOTE: Baseline pruritus NRS average score for maximum itch intensity will be determined based on the average of daily NRS scores for maximum intensity (the daily score ranges from 0 to 10) during the 7 days immediately preceding the Day 1/Baseline visit. A minimum of 4 daily scores out of the 7 days is required to calculate the baseline average score.

  • Participants/Caregivers must be willing and able to complete a daily symptom e-Diary for the duration of the study.
  • use by male and female participants should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion criteria

Exclusion Criteria:

Participants are excluded from the study if any of the following criteria apply:

  • Presence of active moderate to severe lesions of atopic dermatitis (AD), and/or other skin conditions that may interfere with the PN diagnosis including but not limited to the following: scabies, psoriasis, lymphomatoid papulosis, habitual picking, dermatitis herpetiformis, sporotrichosis, and bullous disease.
  • Active chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 2 weeks before the screening visit or during the screening period.

NOTE: Participants may be rescreened after infection resolves.

  • Known or suspected immunodeficiency, including history of invasive opportunistic infections (eg, histoplasmosis, listeriosis, coccidioidomycosis, pneumocystosis, and aspergillosis) despite infection resolution, or otherwise recurrent infections of abnormal frequency or prolonged duration suggesting an immune compromised status, as judged by the Investigator.
  • Severe concomitant illness(es) that, in the Investigator's judgment, would adversely affect the participant's participation in the study.
  • Planned or anticipated major surgical procedure during the participant's participation in this clinical trial.
  • Participants who has taken biologic therapy/systemic / immunomodulator within 4 weeks before the screening visit or 5 half-lives, whichever is longer.
  • Current participation to any clinical trial of an drug or device or participation within 3 months before the screening visit or 5 half-lives of the investigational compound, whichever is longer.
  • Participation in prior dupilumab clinical study or have been treated with commercially available dupilumab.

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
18 participants (estimated)

Study arms

  • Experimental
    Dupilumab

    Administered subcutaneously (SC) based on weight and age

    Drug: Dupilumab

Interventions

  • Pharmaceutical form: Injection solution Route of administration: Subcutaneous

    Also known as: SAR231893, Dupixent

06

What researchers measure

Primary outcomes

  1. Concentration of dupilumab in serum

    Concentration of dupilumab in serum over time

    Time frame: Day 1 to Week 40

Secondary outcomes

  1. Incidence of treatment-emergent adverse events (TEAEs) or serious adverse events (SAEs)

    Time frame: Date of signed ICF (2-4 weeks before Day 1) to Week 40

  2. Incidence of anti-drug antibodies (ADA) to dupilumab over time

    Time frame: Day 1 to Week 40

07

Study locations

15 of 15 sites recruiting
  • Stanford University Medical Center (CTRU)- Site Number : 8400021
    Palo Alto, California 94304, United States
    Recruiting
  • Mission Dermatology Center- Site Number : 8400011
    Rancho Santa Margarita, California 92688, United States
    Recruiting
  • Golden State Dermatology - Walnut Creek - Ygnacio Valley Road- Site Number : 8400023
    Walnut Creek, California 94598, United States
    Recruiting
  • Pediatric Center of Excellence (PCE) - Miami Pediatric Endocrinology- Site Number : 8400005
    Coral Gables, Florida 33146, United States
    Recruiting
  • Life Clinical Trials - Coral Springs- Site Number : 8400018
    Coral Springs, Florida 33071, United States
    Recruiting
  • Direct Helpers Research Center- Site Number : 8400015
    Hialeah, Florida 33012, United States
    Recruiting
  • SunCoast Skin Solutions - Lutz- Site Number : 8400008
    Lutz, Florida 33558, United States
    Recruiting
  • USF Health- Site Number : 8400003
    Tampa, Florida 33606, United States
    Recruiting
  • Tareen Dermatology - Eagan- Site Number : 8400022
    Eagan, Minnesota 55123, United States
    Recruiting
  • MediSearch Clinical Trials- Site Number : 8400004
    Saint Joseph, Missouri 64506, United States
    Recruiting
  • AXIS Clinicals - Fargo- Site Number : 8400013
    Fargo, North Dakota 58103, United States
    Recruiting
  • Vital Prospects Clinical Research Institute - Tulsa- Site Number : 8400002
    Tulsa, Oklahoma 74136, United States
    Recruiting
  • Dell Children's Medical Center- Site Number : 8400007
    Austin, Texas 78723, United States
    Recruiting
  • Driscoll Children's Hospital- Site Number : 8400017
    Corpus Christi, Texas 78411, United States
    Recruiting
  • Oakwell Clinical Research- Site Number : 8400020
    San Antonio, Texas 78218, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2024 (actual). Primary completion is estimated for Oct 2027, 41 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2024
First posted
Mar 5, 2024
StartActual
May 15, 2024
Primary completionEst.
Oct 28, 2027
CompletionEst.
Nov 3, 2027
Last update
Oct 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 2 sites removed
Show 3 added (3 United States)
  • Stanford University Medical Center (CTRU)- Site Number : 8400021 · Palo Alto, United States
  • Golden State Dermatology - Walnut Creek - Ygnacio Valley Road- Site Number : 8400023 · Walnut Creek, United States
  • Oakwell Clinical Research- Site Number : 8400020 · San Antonio, United States
Show 2 removed
  • Stanford University Medical Center CTRU - 800 Welch Road- Site Number : 8400021 · Palo Alto, United States
  • Texas Dermatology and Laser Specialists - San Antonio - Oakwell Court- Site Number : 8400020 · San Antonio, United States
Oct 13, 2026
Eligibility
1 exclusion criterion added
What changed in the criteria
Exclusion criteria
  • AddedThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
Oct 13, 2026
Show all 1 update
  1. Oct 13, 2026
    3 sites added, 2 sites removed
    Show 3 added (3 United States)
    • Stanford University Medical Center (CTRU)- Site Number : 8400021 · Palo Alto, United States
    • Golden State Dermatology - Walnut Creek - Ygnacio Valley Road- Site Number : 8400023 · Walnut Creek, United States
    • Oakwell Clinical Research- Site Number : 8400020 · San Antonio, United States
    Show 2 removed
    • Stanford University Medical Center CTRU - 800 Welch Road- Site Number : 8400021 · Palo Alto, United States
    • Texas Dermatology and Laser Specialists - San Antonio - Oakwell Court- Site Number : 8400020 · San Antonio, United States
    Eligibility 1 exclusion criterion added
    What changed in the criteria
    Exclusion criteria
    • AddedThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
    + 2 other changes: verification date and references

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06293053
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 5, 2024
Start date
May 15, 2024
Primary completion
Oct 28, 2027 (estimated)
Completion
Nov 3, 2027 (estimated)
Last update
Oct 13, 2026

Study contacts

Trial Transparency email recommended (Toll free for US & Canada)
Contact
contact-us@sanofi.com
800-633-1610 ext. option 6

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dupilumab

Start the discussion